Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omaveloxolone PK with CYP3A4 Inducer
NCT05909644Phase 1Completed
- Sponsor
- Biogen
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of omaveloxolone in Friedreich's ataxia (FA), sponsored by Biogen. Primary endpoints: Maximum concentration (Cmax) of omaveloxolone at 43 days, Area under the plasma concentration-time curve from 0 to tlast at 43 days and 1 more. Started Jul 2023; status: completed.
02
Drugs
omaveloxolone
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT05909644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909644.